To learn more about this report, Request sample copy
North America Biopharmaceutical and Biomedicine Market Trends
In North America, the dominance in the biopharmaceutical and biomedicine market with a share of 38.4% in 2024 can be attributed to robust research and development funding, presence of leading global pharmaceutical companies, and favorable regulatory environment conducive for drug innovation. The region also attracts significant investment and business opportunities due to its highly skilled workforce and sophisticated healthcare infrastructure.
Asia Pacific Biopharmaceutical and Biomedicine Market Trends
Meanwhile, the Asia Pacific region exhibits the fastest growth and emerging as an important hub with share of 28.7% in 2024. Major factors driving the growth include rising healthcare expenditure, growing middle-class demographics seeking higher quality care, and government initiatives encouraging local manufacturing and international partnerships. Leading players such as GSK Plc are particularly leveraging opportunities in China, India, and Southeast Asian countries.
Biopharmaceutical and Biomedicine Market Outlook for Key Countries
United States Biopharmaceutical and Biomedicine Market Trends
The U.S. leads the biopharmaceutical sector, with substantial investments in research and development. In December 2022, members of the Pharmaceutical Research and Manufacturers of America (PhRMA) invested approximately US$ 101 billion in R&D, underscoring the country's commitment to innovation.
Germany Biopharmaceutical and Biomedicine Market Trends
Germany is a leader in Europe for biopharmaceuticals, supported by strong regulatory frameworks and funding for research. In October 2024, the German government announced a US$ 1.04 billion investment in biotechnology research, aimed at enhancing the development of innovative therapies. This initiative is likely to accelerate advancements in the sector.
China Biopharmaceutical and Biomedicine Market Trends
Th China biopharmaceutical market is expanding rapidly, attracting global pharmaceutical companies seeking acquisitions to enhance their drug pipelines. In February 2024, AstraZeneca acquired Gracell Biotechnologies for US$ 1.2 billion, reflecting the strategic interest in China's innovative biotech firms.
Japan Biopharmaceutical and Biomedicine Market Trends
Japan’s expanding capabilities in biopharmaceutical manufacturing and its focus on cutting-edge therapies position it as a global leader in the industry. AGC Inc., a world-leading manufacturer of glass, is investing approximately 50 billion to expand its biopharmaceutical contract development and manufacturing organization (CDMO) capabilities at its Yokohama Technical Center in Japan. The expansion will support the development of gene and cell therapies starting in 2025, and manufacturing services for mRNA pharmaceuticals, biopharmaceuticals using mammalian cell cultures by 2026.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients